H.I.G. Capital News
MacDougall Biomedical Communications
NeurAxon, Inc. to Present at Lazard Capital Markets 7th Annual Healthcare Conference November 16, 2010
WALTHAM, MA - November 9, 2010 - NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference taking place November 16-17, 2010 in New York City.
The NeurAxon presentation will be delivered on Tuesday, November 16, 2010 at 2:10 pm Eastern Time at the St. Regis New York in the Watteau Room.
Dr. Bloch will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 clinical development for the treatment of acute migraine.
About NeurAxon Inc.
NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.